ArticleInternational journal of chronic obstructive pulmonary disease2026
LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow limitation, largely driven by airway remodeling. Epithelial-mesenchymal transition (EMT) is a key mechanism underlying this process. Laminin subunit gamma-2 (LAMC2) is implicated in fibrosis and EMT, but its role in COPD-associated airway remodeling remains unclear. Methods: Differential expression analysis was performed using airway epithelial cell datasets from COPD patients and TGF-β1-induced EMT models. Findings were validated in COPD patient lung tissues, smoke-exposed mice, and in vitro experiments. In vivo, chronic smoke-exposed mice were pre-treated intratracheally with adeno-associated virus (AAV)-shLAMC2. Functional assays involved siRNA knockdown or plasmid overexpression of LAMC2 in bronchial epithelial cells. RNA sequencing and pathway analyses were conducted to explore underlying mechanisms. Results: LAMC2 was significantly upregulated in COPD patient and murine airway epithelia. AAV-shLAMC2 administration alleviated airway remodeling and restored epithelial E-cadherin while reducing mesenchymal markers (N-cadherin, fibronectin), indicating attenuation of EMT. In vitro, LAMC2 was upregulated in TGF-β1-stimulated epithelial cells, and its modulation significantly influenced EMT progression. Transcriptomic analysis suggested that AKT signaling as a potential downstream of LAMC2, supported by functional assays. Conclusion: LAMC2 is upregulated in COPD airway epithelium and promotes airway remodeling by regulating EMT, potentially through AKT signaling. These findings suggest that targeting LAMC2 may represent a potential strategy for mitigating COPD-associated airway remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.